QureTech Bio develops new synthetic antibacterial agents that address significant medical need in infectious disease. The compounds are new small molecules from a well-developed chemical platform that are protected by strong intellectual property.

The company’s lead program is focused on developing a new class of antibiotics. The GmPcides are bactericidal against Gram-positive bacteria, such as Staphylococcus aureus, Streptococcus pyogenes and Enterococcus ssp, including drug-resistant strains such as MRSA and VRE. No resistance development has been detected in vitro or in clinical isolates. Read more about the GmPcide program here.